SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells

Cancer Letters

Volumn 318, Issue 2, 2012, Pages 180-188

  Liu, Kai Sheng ^a   Liu, Hui ^a   Qi, Jin Huan ^b   Liu, Qiu Yun ^b   Liu, Zhong ^a   Xia, Min ^a   Xing, Guo Wen ^c   Wang, Shao Xiang ^a   Wang, Yi Fei ^a  

^a JINAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c BEIJING NORMAL UNIVERSITY   (China)

Author keywords

A 375; Apoptosis; Autophagy; Hsp90 client proteins; Hsp90 inhibitor; SNX 2112

Indexed keywords

B RAF KINASE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CHECKPOINT KINASE 1; DEATH RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 CLIENT PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; I KAPPA B KINASE ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE B; S6 KINASE; SNX 2112; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN A 375; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MELANOMA; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; REGULATORY MECHANISM; TIME;

APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL LINE, TUMOR; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IN SITU NICK-END LABELING; MELANOMA; MICROSCOPY, ELECTRON, SCANNING;

EID: 84858152476     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.015     Document Type: Article

References (54)

1. Blagg B.S.J., Bishop S.C., Burlison J.A. Hsp90: a novel target for the disruption of multiple signaling cascades. Curr. Cancer Drug Targets 2007, 7:369-388.
2. Zuehlke A., Johnson J.L. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 2010, 93:211-217.
3. Pearl L.H., Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75:271-294.
4. Zhang H., Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. (Berl) 2004, 82:488-499.
5. Solit D.B., Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov. Today 2008, 13:38-43.
6. Brown M.A., Zhu L., Schmidt C., Tucker P.W. Hsp90 - from signal transduction to cell transformation. Biochem. Biophys. Res. Commun. 2007, 363:241-246.
7. Neckers L., Mimnaugh E., Schulte T.W. Hsp90 as an anti-cancer target. Drug Resist. Updates 1999, 2:165-172.
8. McCarthy M.M., Pick E., Kluger Y., Gould-Rothberg B., Lazova R., Camp R.L., Rimm D.L., Kluger H.M. HSP90 as a marker of progression in melanoma. Ann. Oncol. 2008, 19:590-594.
9. Pick E., Kluger Y., Giltnane J.M., Moeder C., Camp R.L., Rimm D.L., Kluger H.M. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007, 67:2932-2937.
10. Gallegos Ruiz M.I., Floor K., Roepman P., Rodriguez J.A., Meijer G.A., Mooi W.J., Jassem E., Niklinski J., Muley T., van Zandwijk N., Smit E.F., Beebe K., Neckers L., Ylstra B., Giaccone G. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One 2008, 3:e0001722.
11. Li C.F., Huang W.W., Wu J.M., Yu S.C., Hu T.H., Uen Y.H., Tian Y.F., Lin C.N., Lu D., Fang F.M., Huang H.Y. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin. Cancer Res. 2008, 14:7822-7831.
12. Porter J.R., Fritz C.C., Depew K.M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr. Opin. Chem. Biol. 2010, 14:412-420.
13. Taldone T., Sun W., Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg. Med. Chem. 2009, 17:2225-2235.
14. Powers M.V., Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr. Relat. Cancer 2006, 13(Suppl 1):S125-135.
15. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
16. Hertlein E., Wagner A.J., Jones J., Lin T.S., Maddocks K.J., Towns W.H., Goettl V.M., Zhang X., Jarjoura D., Raymond C.A., West D.A., Croce C.M., Byrd J.C., Johnson A.J. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010, 116:45-53.
17. Chiu H.W., Lin J.H., Chen Y.A., Ho S.Y., Wang Y.J. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy 2010, 6:353-365.
18. Chang H.Y., Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 2000, 64:821-846.
19. Jin L., Xiao C.L., Lu C.H., Xia M., Xing G.W., Xiong S., Liu Q.Y., Liu H., Li Y.C., Ge F. Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS Lett. 2009, 583:1859-1866.
20. Kim Y.J., Lee S.A., Myung S.C., Kim W., Lee C.S. Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins. Mol. Cell. Biochem. 2011.
21. Xu C., Liu J., Hsu L.C., Luo Y., Xiang R., Chuang T.H. Functional interaction of Hsp90 and Beclin 1 modulates toll-like receptor-mediated autophagy. FASEB J. 2011.
22. Palacios C., Martín-Pérez R., López-Pérez A.I., Pandiella A., López-Rivas A. Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk. Res. 2010, 34:1533-1538.
23. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5:726-734.
24. Gozuacik D., Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004, 23:2891-2906.
25. Roca H., Varsos Z., Pienta K.J. CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J. Biol. Chem. 2008, 283:25057-25073.
26. Rami A., Kogel D. Apoptosis meets autophagy-like cell death in the ischemic penumbra: two sides of the same coin?. Autophagy 2008, 4:422-426.
27. Okawa Y., Hideshima T., Steed P., Vallet S., Hall S., Huang K., Rice J., Barabasz A., Foley B., Ikeda H., Raje N., Kiziltepe T., Yasui H., Enatsu S., Anderson K.C. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113:846-855.
28. Bachleitner-Hofmann T., Sun M.Y., Chen C.T., Liska D., Zeng Z., Viale A., Olshen A.B., Mittlboeck M., Christensen J.G., Rosen N., Solit D.B., Weiser M.R. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition. Clin. Cancer Res. 2011, 17:122-133.
29. Steed R., Huang H., Fadden P., Rice J., Eaves J., Barbasz A., Foley B., Partridge J., Scott A., Hall S. SNX-2112: a novel, selective, potent small molecule inhibitor of Hsp90 with unique pharmacodynamic properties. Ejc Suppl. 2006, 4:165.
30. Barta T.E., Veal J.M., Rice J.W., Partridge J.M., Fadden R.P., Ma W., Jenks M., Geng L., Hanson G.J., Huang K.H., Barabasz A.F., Foley B.E., Otto J., Hall S.E. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg. Med. Chem. Lett. 2008, 18:3517-3521.
31. Shinojima N., Yokoyama T., Kondo Y., Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy. Autophagy 2007, 3:635-637.
32. Wang C.C.C., Chiang Y.M., Sung S.C., Hsu Y.L., Chang J.K., Kuo P.L. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett. 2008, 259:82-98.
33. Hamm C., Verma S., Petrella T., Bak K., Charette M. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat. Rev. 2008, 34:145-156.
34. Georgakis G.V., Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol. 2005, 1:273-281.
35. Chandarlapaty S., Sawai A., Ye Q., Scott A., Silinski M., Huang K., Fadden P., Partdrige J., Hall S., Steed P., Norton L., Rosen N., Solit D.B. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin. Cancer Res. 2008, 14:240-248.
36. Gong X.F., Wang M.W., Tashiro S., Onodera S., Ikejima T. Pseudolaric acid B induces apoptosis through p53 and Bax/Bcl-2 pathways in human melanoma A375-S2 cells. Arch. Pharm. Res. 2005, 28:68-72.
37. Luo Y., Leverson J.D. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Expert Rev. Anticancer Ther. 2005, 5:333-342.
38. Panka D.J., Cho D.C., Atkins M.B., Mier J.W. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J. Biol. Chem. 2008, 283:726-732.
39. Papp T., Niemetz A., Dosdahl N., Kumar K., Schiffmann D. Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines. Oncol. Rep. 2007, 17:135-140.
40. Russo A.E., Torrisi E., Bevelacqua Y., Perrotta R., Libra M., McCubrey J.A., Spandidos D.A., Stivala F., Malaponte G. Melanoma: molecular pathogenesis and emerging target therapies (review). Int. J. Oncol. 2009, 34:1481-1489.
41. Yin M.J., Mehta P.P., Kung P.P., Yamazaki S., Walls M., Shen A., Nguyen L., Gehring M.R., Los G., Smeal T. A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells. Cancer Lett. 2011, 300:30-39.
42. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
43. Park K., Choi K., Kim H., Kim K., Lee M.H., Lee J.H., Kim Rim J.C. Isoflavone-deprived soy peptide suppresses mammary tumorigenesis by inducing apoptosis. Exp. Mol. Med. 2009, 41:371-381.
44. Sobczak I., Galabova-Kovacs G., Sadzak I., Kren A., Christofori G., Baccarini M. B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis. Oncogene 2008, 27:4779-4787.
45. Kurashina R., Ohyashiki J.H., Kobayashi C., Hamamura R., Zhang Y., Hirano T., Ohyashiki K. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett. 2009, 284:62-70.
46. Nomura M., Nomura N., Yamashita J. Geldanamycin-induced degradation of Chk1 is mediated by proteasome. Biochem. Biophys. Res. Commun. 2005, 335:900-905.
47. Emanuel P.O., Phelps R.G., Mudgil A., Shafir M., Burstein D.E. Immunohistochemical detection of XIAP in melanoma. J. Cutan. Pathol. 2008, 35:292-297.
48. Liang H., Salinas R.A., Leal B.Z., Kosakowska-Cholody T., Michejda C.J., Waters S.J., Herman T.S., Woynarowski J.M., Woynarowska B.A. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. Mol. Cancer Ther. 2004, 3:1385-1396.
49. Sanchez-Alcazar J.A., Khodjakov A., Schneider E. Anticancer drugs induce increased mitochondrial cytochrome c expression that precedes cell death. Cancer Res. 2001, 61:1038-1044.
50. Rudner J., Elsaesser S.J., Muller A.C., Belka C., Jendrossek V. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem. Pharmacol. 2010, 79:10-20.
51. Morales-Ducret C.R., van de Rijn M., LeBrun D.P., Smoller B.R. bcl-2 expression in primary malignancies of the skin. Arch. Dermatol. 1995, 131:909-912.
52. Liu B., Cheng Y., Zhang B., Bian H.J., Bao J.K. Polygonatum cyrtonema lectin induces apoptosis and autophagy in human melanoma A375 cells through a mitochondria-mediated ROS-p38-p53 pathway. Cancer Lett. 2009, 275:54-60.
53. Wang Q., Chen Z., Diao X., Huang S. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer Lett. 2011, 302:29-36.
54. Saiki S., Sasazawa Y., Imamichi Y., Kawajiri S., Fujimaki T., Tanida I., Kobayashi H., Sato F., Sato S., Ishikawa K., Imoto M., Hattori N. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy 2011, 7:176-187.